SG11201806433VA - Composition and combined medication method for treating enterovirus infection - Google Patents
Composition and combined medication method for treating enterovirus infectionInfo
- Publication number
- SG11201806433VA SG11201806433VA SG11201806433VA SG11201806433VA SG11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA
- Authority
- SG
- Singapore
- Prior art keywords
- composition
- enterovirus infection
- combined medication
- medication method
- treating
- Prior art date
Links
- 206010014909 Enterovirus infection Diseases 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 241000709661 Enterovirus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610067164.5A CN105688216B (zh) | 2016-01-29 | 2016-01-29 | 治疗肠道病毒感染的组分和联合用药方法 |
CN201610067175.3A CN105664166B (zh) | 2016-01-29 | 2016-01-29 | 一种治疗肠道病毒感染的组合物和联合用药方法 |
PCT/CN2017/070858 WO2017128950A1 (zh) | 2016-01-29 | 2017-01-11 | 一种治疗肠道病毒感染的组合物和联合用药方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806433VA true SG11201806433VA (en) | 2018-08-30 |
Family
ID=59397381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806433VA SG11201806433VA (en) | 2016-01-29 | 2017-01-11 | Composition and combined medication method for treating enterovirus infection |
Country Status (6)
Country | Link |
---|---|
US (1) | US10864210B2 (ja) |
JP (1) | JP6644917B2 (ja) |
AU (1) | AU2017210921B2 (ja) |
MY (1) | MY201019A (ja) |
SG (1) | SG11201806433VA (ja) |
WO (1) | WO2017128950A1 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145608B (zh) * | 2011-12-07 | 2015-09-02 | 南开大学 | 抗肠病毒71(ev71)己内酰胺类化合物及其制备方法和用途 |
CN105688216B (zh) * | 2016-01-29 | 2019-01-25 | 中国科学院上海巴斯德研究所 | 治疗肠道病毒感染的组分和联合用药方法 |
CN105664166B (zh) * | 2016-01-29 | 2019-05-10 | 中国科学院上海巴斯德研究所 | 一种治疗肠道病毒感染的组合物和联合用药方法 |
-
2017
- 2017-01-11 SG SG11201806433VA patent/SG11201806433VA/en unknown
- 2017-01-11 JP JP2018558467A patent/JP6644917B2/ja active Active
- 2017-01-11 WO PCT/CN2017/070858 patent/WO2017128950A1/zh active Application Filing
- 2017-01-11 US US16/073,487 patent/US10864210B2/en active Active
- 2017-01-11 MY MYPI2018702616A patent/MY201019A/en unknown
- 2017-01-11 AU AU2017210921A patent/AU2017210921B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6644917B2 (ja) | 2020-02-12 |
AU2017210921A1 (en) | 2018-08-16 |
WO2017128950A1 (zh) | 2017-08-03 |
JP2019509331A (ja) | 2019-04-04 |
US20190030027A1 (en) | 2019-01-31 |
AU2017210921B2 (en) | 2020-01-02 |
MY201019A (en) | 2024-01-30 |
US10864210B2 (en) | 2020-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
PH12016501379A1 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
MX2019010404A (es) | Compuestos sulfamida cíclicos y métodos de uso de los mismos. | |
MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
EA030115B9 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
MX2019007256A (es) | Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano. | |
MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
PH12018501962A1 (en) | Stablizied soluble pre-fusion rsv f proteins | |
MX2020004060A (es) | Metodos para el tratamiento de infeccion de hepatitis b. | |
MX2016016722A (es) | Coronavirus. | |
SG10201908697XA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
MX2021007602A (es) | Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b. | |
MX2021004464A (es) | Compuestos de tiazolida para el tratamiento de infecciones virales. | |
MX2017000312A (es) | Derivados de isoindolina para usarse en el tratamiento de una infeccion viral. | |
EP3681508A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF VIRAL INFECTION | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
EP3658679C0 (en) | METHOD FOR THE RAPID DETECTION AND COUNTING OF VIRUSES, BACTERIOPHAGES AND/OR BACTERIA | |
PH12017502386B1 (en) | Methods of purification and/or viral inactivation | |
MX2021006326A (es) | Inhibidores de pcna. | |
PH12017550047B1 (en) | Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus |